An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorLEON, J. de
dc.contributor.authorSCHORETSANITIS, G.
dc.contributor.authorSMITH, R. L.
dc.contributor.authorMOLDEN, E.
dc.contributor.authorSOLISMAA, A.
dc.contributor.authorSEPPäLä, N.
dc.contributor.authorKOPEčEK, M.
dc.contributor.authorŠVANCER, P.
dc.contributor.authorOLMOS, I.
dc.contributor.authorRICCIARDI, C.
dc.contributor.authorIGLESIAS-GARCIA, C.
dc.contributor.authorORTIZ, B. B.
dc.contributor.authorELKIS, H.
dc.contributor.authorPALHA, A. J. Pacheco
dc.contributor.authorLLERENA, A.
dc.contributor.authorFERNANDEZ-EGEA, E.
dc.contributor.authorSISKIND, D.
dc.contributor.authorWEIZMAN, A.
dc.contributor.authorMASMOUDI, R.
dc.contributor.authorSAFFIAN, S. Mohd
dc.contributor.authorLEUNG, J. G.
dc.contributor.authorBUCKLEY, P. F.
dc.contributor.authorMARDER, S. R.
dc.contributor.authorCITROME, L.
dc.contributor.authorFREUDENREICH, O.
dc.contributor.authorCORRELL, C. U.
dc.contributor.authorMüLLER, D. J.
dc.contributor.authorIGLESIAS-ALONSO, A.
dc.contributor.authorSPINA, E.
dc.contributor.authorRUAN, C.-J.
dc.contributor.authorWANG, C.-Y.
dc.contributor.authorWANG, G.
dc.contributor.authorTANG, Y.-L.
dc.contributor.authorLIN, S.-K.
dc.contributor.authorLANE, H.-Y.
dc.contributor.authorKIM, Y. S.
dc.contributor.authorKIM, S. H.
dc.contributor.authorRAJKUMAR, A. P.
dc.contributor.authorGONZáLEZ-ESQUIVEL, D. F.
dc.contributor.authorJUNG-COOK, H.
dc.contributor.authorBAPTISTA, T.
dc.contributor.authorROHDE, C.
dc.contributor.authorNIELSEN, J.
dc.contributor.authorVERDOUX, H.
dc.contributor.authorQUILES, C.
dc.contributor.authorSANZ, E. J.
dc.contributor.authorCUEVAS, C. De las
dc.contributor.authorCOHEN, D.
dc.contributor.authorSCHULTE, P. F. J.
dc.contributor.authorERTUğRUL, A.
dc.contributor.authorYAğCıOğLU, A. E. Anıl
dc.contributor.authorCHOPRA, N.
dc.contributor.authorMCCOLLUM, B.
dc.contributor.authorSHELTON, C.
dc.contributor.authorCOTES, R. O.
dc.contributor.authorKAITHI, A. R.
dc.contributor.authorKANE, J. M.
dc.contributor.authorFAROOQ, S.
dc.contributor.authorNG, C. H.
dc.contributor.authorBILBILY, J.
dc.contributor.authorHIEMKE, C.
dc.contributor.authorLóPEZ-JARAMILLO, C.
dc.contributor.authorMCGRANE, I.
dc.contributor.authorLANA, F.
dc.contributor.authorEAP, C. B.
dc.contributor.authorARROJO-ROMERO, M.
dc.contributor.authorRăDULESCU, F.Ş.
dc.contributor.authorSEIFRITZ, E.
dc.contributor.authorEVERY-PALMER, S.
dc.contributor.authorBOUSMAN, C. A.
dc.contributor.authorBEBAWI, E.
dc.contributor.authorBHATTACHARYA, R.
dc.contributor.authorKELLY, D. L.
dc.contributor.authorOTSUKA, Y.
dc.contributor.authorLAZARY, J.
dc.contributor.authorTORRES, R.
dc.contributor.authorYECORA, A.
dc.contributor.authorMOTUCA, M.
dc.contributor.authorCHAN, S. K. W.
dc.contributor.authorZOLEZZI, M.
dc.contributor.authorOUANES, S.
dc.contributor.authorBERARDIS, D. De
dc.contributor.authorGROVER, S.
dc.contributor.authorPROCYSHYN, R. M.
dc.contributor.authorADEBAYO, R. A.
dc.contributor.authorKIRILOCHEV, O. O.
dc.contributor.authorSOLOVIEV, A.
dc.contributor.authorFOUNTOULAKIS, K. N.
dc.contributor.authorWILKOWSKA, A.
dc.contributor.authorCUBAłA, W. J.
dc.contributor.authorAYUB, M.
dc.contributor.authorSILVA, A.
dc.contributor.authorBONELLI, R. M.
dc.contributor.authorVILLAGRáN-MORENO, J. M.
dc.contributor.authorCRESPO-FACORRO, B.
dc.contributor.authorTEMMINGH, H.
dc.contributor.authorDECLOEDT, E.
dc.contributor.authorPEDRO, M. R.
dc.contributor.authorTAKEUCHI, H.
dc.contributor.authorTSUKAHARA, M.
dc.contributor.authorGRüNDER, G.
dc.contributor.authorSAGUD, M.
dc.contributor.authorCELOFIGA, A.
dc.contributor.authorRISTIC, D. Ignjatovic
dc.date.accessioned2024-03-13T19:57:34Z
dc.date.available2024-03-13T19:57:34Z
dc.date.issued2023
dc.description.abstractThis is the Spanish translation of an international guideline which proposes improving clozapine package inserts worldwide by using ancestry-based: 1) dosing and 2) titration. Adverse drug reaction (ADR) databases suggest clozapine: 1) is the third most toxic drug in the United States (US), and 2) produces worldwide pneumonia mortality four times greater than that of agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers require the lowest dose and male smokers the highest dose). Poor metabolizer (PM) status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity or inflammation with C-reactive protein (CRP) elevations. People with ancestry from Asia (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/ml. Daily doses of 300-600 mg/day are recommended in the US. Slow personalized titration may prevent early ADRs (including syncope, myocarditis and pneumonia). The core of this guideline consists of six personalized titration schedules for inpatients: 1) Asian/Amerindian ancestry with lower metabolism (in cases of obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) Asian/Amerindian ancestry with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (in cases of obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US of non-Asian/Amerindian ancestry with lower clozapine metabolism (in cases of obesity or valproate) needing 150-300 mg/day, and 6) in the US of non-Asian/Amerindian ancestry with average clozapine metabolism needing 300-600 mg/day. Baseline and weekly CRP monitoring for at least 4 weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.eng
dc.description.indexScopus
dc.description.indexDimensions
dc.identifier.citationPSIQUIATRIA BIOLOGICA, v.30, n.3, article ID 100415, p, 2023
dc.identifier.doi10.1016/j.psiq.2023.100415
dc.identifier.issn1134-5934
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58638
dc.language.isoeng
dc.publisherSOCIEDAD ESPANOLA DE PSIQUIATRIA BIOLOGICA (SEPB)eng
dc.relation.ispartofPsiquiatria Biologica
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright SOCIEDAD ESPANOLA DE PSIQUIATRIA BIOLOGICA (SEPB)eng
dc.subjectAsian continental ancestry groupeng
dc.subjectClozapine/adverse effectseng
dc.subjectClozapine/bloodeng
dc.subjectClozapine/metabolismeng
dc.subjectClozapine/therapeutic useeng
dc.subjectClozapine/toxicityeng
dc.subjectCYP1A2eng
dc.subjectDrug labelingeng
dc.subjectEuropean continental ancestry groupeng
dc.subjectInfectioneng
dc.subjectInflammationeng
dc.subjectMortality/drug effectseng
dc.subjectNative American continental ancestry groupeng
dc.subjectSexeng
dc.subjectSmokingeng
dc.subject.otherc reactive proteineng
dc.subject.otherclozapineeng
dc.subject.othercytochrome p450 1a2eng
dc.subject.othervalproic acideng
dc.subject.otheradulteng
dc.subject.otheragranulocytosiseng
dc.subject.otheramerican indianeng
dc.subject.otherancestry groupeng
dc.subject.otherarticleeng
dc.subject.otherasiaeng
dc.subject.otherasian continental ancestry groupeng
dc.subject.otherblood leveleng
dc.subject.othercaucasianeng
dc.subject.otherclinical articleeng
dc.subject.othercontrolled studyeng
dc.subject.otherdrug effecteng
dc.subject.otherdrug labelingeng
dc.subject.otherenzyme activityeng
dc.subject.otherfaintnesseng
dc.subject.otherfemaleeng
dc.subject.otherhumaneng
dc.subject.otherhuman tissueeng
dc.subject.otherinflammationeng
dc.subject.otherjapaneng
dc.subject.othermaleeng
dc.subject.othermetabolismeng
dc.subject.othermortalityeng
dc.subject.othermyocarditiseng
dc.subject.othernon-smokereng
dc.subject.otherobesityeng
dc.subject.otherpakistaneng
dc.subject.otherpneumoniaeng
dc.subject.otherpractice guidelineeng
dc.subject.otherprescriptioneng
dc.subject.othersmokingeng
dc.subject.othersteady stateeng
dc.subject.othertherapeutic doseeng
dc.subject.othertitrimetryeng
dc.subject.otherunited stateseng
dc.titleAn international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levelseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryChina
hcfmusp.affiliation.countryTaiwan
hcfmusp.affiliation.countryCoréia do Sul
hcfmusp.affiliation.countryReino Unido
hcfmusp.affiliation.countryMéxico
hcfmusp.affiliation.countryVenezuela
hcfmusp.affiliation.countryDinamarca
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryHolanda
hcfmusp.affiliation.countryTurquia
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryAustrália
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countryColômbia
hcfmusp.affiliation.countrySuíça
hcfmusp.affiliation.countryRomênia
hcfmusp.affiliation.countryNova Zelândia
hcfmusp.affiliation.countryJapão
hcfmusp.affiliation.countryHungria
hcfmusp.affiliation.countryChile
hcfmusp.affiliation.countryArgentina
hcfmusp.affiliation.countryCatar
hcfmusp.affiliation.countryÍndia
hcfmusp.affiliation.countryNigéria
hcfmusp.affiliation.countryRússia
hcfmusp.affiliation.countryGrécia
hcfmusp.affiliation.countryPolônia
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryÁustria
hcfmusp.affiliation.countryÁfrica do Sul
hcfmusp.affiliation.countryMoçambique
hcfmusp.affiliation.countryCroácia
hcfmusp.affiliation.countryEslovênia
hcfmusp.affiliation.countrySérvia
hcfmusp.affiliation.countryIsrael
hcfmusp.affiliation.countryTunísia
hcfmusp.affiliation.countryMalásia
hcfmusp.affiliation.countryEspanha
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryNoruega
hcfmusp.affiliation.countryFinlândia
hcfmusp.affiliation.countryRepública Tcheca
hcfmusp.affiliation.countryUruguai
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisoes
hcfmusp.affiliation.countryisono
hcfmusp.affiliation.countryisofi
hcfmusp.affiliation.countryisocz
hcfmusp.affiliation.countryisouy
hcfmusp.affiliation.countryisokr
hcfmusp.affiliation.countryisomx
hcfmusp.affiliation.countryisoau
hcfmusp.affiliation.countryisoil
hcfmusp.affiliation.countryisotn
hcfmusp.affiliation.countryisomy
hcfmusp.affiliation.countryisode
hcfmusp.affiliation.countryisoca
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisocn
hcfmusp.affiliation.countryisotw
hcfmusp.affiliation.countryisove
hcfmusp.affiliation.countryisodk
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisonl
hcfmusp.affiliation.countryisotr
hcfmusp.affiliation.countryisoco
hcfmusp.affiliation.countryisoch
hcfmusp.affiliation.countryisoro
hcfmusp.affiliation.countryisonz
hcfmusp.affiliation.countryisojp
hcfmusp.affiliation.countryisohu
hcfmusp.affiliation.countryisocl
hcfmusp.affiliation.countryisoar
hcfmusp.affiliation.countryisoqa
hcfmusp.affiliation.countryisoin
hcfmusp.affiliation.countryisong
hcfmusp.affiliation.countryisoru
hcfmusp.affiliation.countryisogr
hcfmusp.affiliation.countryisopl
hcfmusp.affiliation.countryisopt
hcfmusp.affiliation.countryisoat
hcfmusp.affiliation.countryisoza
hcfmusp.affiliation.countryisomz
hcfmusp.affiliation.countryisohr
hcfmusp.affiliation.countryisosi
hcfmusp.affiliation.countryisors
hcfmusp.author.externalLEON, J. de:Centro de Investigación de Salud Mental, Hospital Eastern State, Lexington, KY, United States, Departamento de Psiquiatría, Universidad de Kentucky, Lexington, KY, United States, Grupo de Investigación de Psiquiatría y Neurociencias (CTS-549), Instituto de Neurociencias, Universidad de Granada, Granada, Spain, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Hospital Santiago Apostol, Universidad del País Basco, Vitoria, Spain
hcfmusp.author.externalSCHORETSANITIS, G.:Departamento de Psiquiatría, Psicoterapia y Psicosomáticos, Hospital Psiquiátrico, Universidad de Zürich, Zürich, Switzerland, Hospital Zucker Hillside, Investigación Psiquiátrica, Northwell Health, Glen Oaks, New York, United States
hcfmusp.author.externalSMITH, R. L.:Centro para la Psicofarmacología, Hospital Diakonhjemmet, Oslo, Norway
hcfmusp.author.externalMOLDEN, E.:Centro para la Psicofarmacología, Hospital Diakonhjemmet, Oslo, Norway, Sección de Farmacología y Biociencias Farmacéuticas, Departamento de Farmacia, Universidad de Oslo, Oslo, Norway
hcfmusp.author.externalSOLISMAA, A.:Facultad de Medicina y Tecnología de la Salud, Universidad Tampere, Tampere, Finland, Departamento de Psiquiatría, Hospital Universitario de Tampere, Tampere, Finland
hcfmusp.author.externalSEPPäLä, N.:Departamento de Psiquiatría, Satasairaala, Finland
hcfmusp.author.externalKOPEčEK, M.:Instituto Nacional de Salud Mental, Klecany, Czech Republic, Departamento de Psiquiatría, Universidad de Charles, Tercera Facultad de Medicina, Praga, Czech Republic
hcfmusp.author.externalŠVANCER, P.:Instituto Nacional de Salud Mental, Klecany, Czech Republic, Departamento de Psiquiatría, Universidad de Charles, Tercera Facultad de Medicina, Praga, Czech Republic
hcfmusp.author.externalOLMOS, I.:Unidad Clínica Farmacológica y Departamento de Farmacia, Hospital Vilardebó, Administración de Servicios de Salud, Montevideo, Uruguay
hcfmusp.author.externalRICCIARDI, C.:Unidad de Farmacología Clínica y Ambulatorio, Hospital Vilardebó, Administración de Servicios de Salud, Montevideo, Uruguay
hcfmusp.author.externalIGLESIAS-GARCIA, C.:CIBERSAM, INEUROPA, ISPA-FIMBA, Universidad de Oviedo, Oviedo, Spain, Unidad de Psiquiatría, Hospital Valle del Nalón, Langreo, Spain
hcfmusp.author.externalFERNANDEZ-EGEA, E.:Centro de Psicósis Cambridge, Fundación Trust Cambrigeshire and Peterborough NHS y Departamento de Psiquiatría, Universidad de Cambridge, Cambridge, United Kingdom
hcfmusp.author.externalSISKIND, D.:Servicio Adicción y Salud Mental Metro South, Brisbane, Australia, Centro de Investigación en Salud Mental y Escuela de Medicina Clínica Queensland, Universidad de Queensland, Brisbane, Australia
hcfmusp.author.externalWEIZMAN, A.:Unidad de Investigación, Centro de Salud Mental y Laboratorio de Psiquiatría Molecular de Geha, Centro Médico de Investigación Felsenstein, Tel Aviv, Israel, Departamento de Psiquiatría Facultad de Medicina Sackler y Escuela Sagol de Neurociencia, Universidad de Tel Aviv, Tel Aviv, Israel
hcfmusp.author.externalMASMOUDI, R.:Departamento de Psiquiatría “A”, Hospital Universitario Hedi Chaker, Sfax, Tunisia, Facultad de Medicina, Universidad de Sfax, Sfax, Tunisia
hcfmusp.author.externalSAFFIAN, S. Mohd:Centro de Gestión de la Calidad de los Medicamentos, Facultad de Farmacia, Universidad de Kebangsaan Malaysia, Kuala Lumpur, Malaysia
hcfmusp.author.externalLEUNG, J. G.:Departamento de Farmacia, Mayo Clinic, Rochester, MN, United States
hcfmusp.author.externalBUCKLEY, P. F.:Escuela de Medicina, Universidad de Virginia Commonwealth, Richmond, VA, United States
hcfmusp.author.externalMARDER, S. R.:Instituto de Neurociencia Semel, Universidad de California, Los Angeles, CA, United States, Centro de Investigación de Enfermedades Mentales, Educación y Centro Clínico en Desert Pacific Virginia, Los Angeles, CA, United States
hcfmusp.author.externalCITROME, L.:Facultad de Medicina, Universidad de New York, Departamento de Psiquiatría y Ciencias del Comportamiento, Valhalla, NY, United States
hcfmusp.author.externalFREUDENREICH, O.:Departamento de Psiquiatría, Hospital General de Massachusetts, Escuela de Medicina de Harvard, Boston, MA, United States
hcfmusp.author.externalCORRELL, C. U.:Hospital Zucker Hillside, Investigación Psiquiátrica, Northwell Health, Glen Oaks, New York, United States, Departamento de Psiquiatría y Medicina Molecular, Escuela de Medicina Donald y Barbara Zucker en Hofstra/Northwell Hempstead, New York, United States, Universidad Charité de Berlin, Departamento de Psiquiatría de Niños y Adolescentes, Berlin, Germany
hcfmusp.author.externalMüLLER, D. J.:División de Adicciones, Centro de Adicciones y Salud Mental, Toronto, Canada, Departamento de Psiquiatría, Universidad de Toronto, Toronto, ON, Canada
hcfmusp.author.externalIGLESIAS-ALONSO, A.:Hospital Universitario Central de Asturias, Oviedo, Spain
hcfmusp.author.externalSPINA, E.:Departamento de Medicina y Clínica Experimental, Universidad de Messina, Messina, Italy
hcfmusp.author.externalRUAN, C.-J.:Laboratorio de Psicofarmacología Clínica, Hospital Beijing Anding, Universidad Capital Medical, Beijing, China, Centro Nacional de Investigación Clínica para Trastornos Mentales y Laboratorio Clave de Trastornos Mentales de Beijing, Hospital Beijing Anding, Universidad Capital Medical, Beijing, China
hcfmusp.author.externalWANG, C.-Y.:Centro Nacional de Investigación Clínica para Trastornos Mentales y Laboratorio Clave de Trastornos Mentales de Beijing, Hospital Beijing Anding, Universidad Capital Medical, Beijing, China, Departamento de Psiquiatría, Hospital Beijing Anding, Universidad Capital Medical, Beijing, China
hcfmusp.author.externalWANG, G.:Centro Nacional de Investigación Clínica para Trastornos Mentales y Laboratorio Clave de Trastornos Mentales de Beijing, Hospital Beijing Anding, Universidad Capital Medical, Beijing, China
hcfmusp.author.externalTANG, Y.-L.:Departamento de Psiquiatría y Ciencias del Comportamiento, Escuela de Medicina, Universidad de Emory, Atlanta, GA, United States, Programa de Tratamiento al Abuso de Sustancias, Centro Médico Atlanta VA, Decatur, GA, United States
hcfmusp.author.externalLIN, S.-K.:Departamento de Psiquiatría, Hospital Linkou Chang Gung Memorial, Taoyuan, China, Departamento de Psiquiatría, Escuela de Medicina, Universidad Médica de Taipei, Taipei, Taiwan
hcfmusp.author.externalLANE, H.-Y.:Instituto de Graduados de Ciencias Médicas, Universidad Médica de China, Taichung, China, Departamento de Psiquiatría y Centro de Investigación de Enfermedades Cerebrales, Hospital Universitario Médico de China, Taichung, China, Departamento de Psicología, Facultad de Ciencias Médicas y de la Salud, Universidad de Asia, Taichung, China
hcfmusp.author.externalKIM, Y. S.:Departamento de Neuropsiquiatría, Centro Médico Nowon Eulji, Universidad Eulji, Escuela de Medicina, Seúl, South Korea
hcfmusp.author.externalKIM, S. H.:Departamento de Psiquiatría, Facultad de Psiquiatría, Universidad Nacional de Seul, Hospital Nacional Universitario de Seúl, Seúl, South Korea
hcfmusp.author.externalRAJKUMAR, A. P.:Departamento de Psiquiatría, Facultad de Medicina Cristiana, Christian Medical College, Vellore, India, Instituto de Mecina Mental, Universidad de Nottingham, Campus Jubilee, Nottingham, United Kingdom
hcfmusp.author.externalGONZáLEZ-ESQUIVEL, D. F.:Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, Mexico
hcfmusp.author.externalJUNG-COOK, H.:Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, Mexico, Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, Mexico
hcfmusp.author.externalBAPTISTA, T.:Departamento de Fisiología, Facultad de Medicina de la Universidad de Los Andes, Mérida, Venezuela
hcfmusp.author.externalROHDE, C.:Departamento de Trastornos Afectivos, Hospital Universitario Aarhus - Psiquiatría, Aarhus, Denmark, Departamento de Medicina Clínica, Universidad de Aarhus, Aarhus, Denmark
hcfmusp.author.externalNIELSEN, J.:Centro de Salud Mental Glostrup, Hospital Universitario de Copenhagen, Copenhagen, Denmark
hcfmusp.author.externalVERDOUX, H.:Centro de Investigación de Salud de la Población de Burdeos, Universidad de Burdeos, Inserm, Burdeus, France
hcfmusp.author.externalQUILES, C.:Centro de Investigación de Salud de la Población de Burdeos, Universidad de Burdeos, Inserm, Burdeus, France
hcfmusp.author.externalSANZ, E. J.:Departamento de Medicina Física y Farmacología, Facultad de Medicina, Universidad de La Laguna, Islas Canarias, Spain, Hospital Universitario de Canarias, Servicio Canario de Salud, Tenerife, Spain
hcfmusp.author.externalCUEVAS, C. De las:Departamento de Medicina Interna, Dermatología y Psiquiatría, Escuela de Medicina, e Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, Islas Canarias, Spain
hcfmusp.author.externalCOHEN, D.:Grupo de Colaboración Holandés sobre Clozapina, Castricum, Netherlands, Equipo FACT en Heerhugowaard, Departamento de Enfermedades Mentales Graves, Servicios de Salud Mental North-Holland North, Netherlands
hcfmusp.author.externalSCHULTE, P. F. J.:Grupo de Colaboración Holandés sobre Clozapina, Castricum, Netherlands, Equipo de Salud Mental Alkmaar, Servicios de Salud Mental Noord-Holland-Noord, Alkmaar, Netherlands
hcfmusp.author.externalERTUğRUL, A.:Departamento de Psiquiatría, Facultad de Medicina, Universidad de Hacettepe, Ankara, Turkey
hcfmusp.author.externalYAğCıOğLU, A. E. Anıl:Departamento de Psiquiatría, Facultad de Medicina, Universidad de Hacettepe, Ankara, Turkey
hcfmusp.author.externalCHOPRA, N.:División de Adicciones, Centro de Adicciones y Salud Mental, Toronto, Canada, Departamento de Psiquiatría, Universidad de Toronto, Toronto, ON, Canada
hcfmusp.author.externalMCCOLLUM, B.:Hospital Eastern State, Lexington, KY, United States
hcfmusp.author.externalSHELTON, C.:Departamento de Psiquiatría, Universidad de Kentucky, Lexington, KY, United States, Hospital Eastern State, Lexington, KY, United States
hcfmusp.author.externalCOTES, R. O.:Programa de Tratamiento al Abuso de Sustancias, Centro Médico Atlanta VA, Decatur, GA, United States
hcfmusp.author.externalKAITHI, A. R.:Centro Hazelwood, Louisville, KY, United States
hcfmusp.author.externalKANE, J. M.:Hospital Zucker Hillside, Investigación Psiquiátrica, Northwell Health, Glen Oaks, New York, United States, Departamento de Psiquiatría y Medicina Molecular, Escuela de Medicina Donald y Barbara Zucker en Hofstra/Northwell Hempstead, New York, United States
hcfmusp.author.externalFAROOQ, S.:Facultad de Medicina, Universidad Keele, Staffordshire, Fundación Midlands Partnership NHS, Staffordshire, United Kingdom
hcfmusp.author.externalNG, C. H.:Departamento de Psiquiatría, The University of Melbourne, Melbourne, VIC, Australia
hcfmusp.author.externalBILBILY, J.:Departamento de Psiquiatría, Universidad Washington en St. Louis, St. Louis, MO, United States
hcfmusp.author.externalHIEMKE, C.:Departamento de Psiquiatría y Psicoterapia, Universidad Centro Médico de Mainz, Germany
hcfmusp.author.externalLóPEZ-JARAMILLO, C.:Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia, Programa Trastornos del Ánimo, Hospital Universitario San Vicente Fundación, Medellín, Colombia
hcfmusp.author.externalMCGRANE, I.:Departamento de Práctica Farmacéutica, Universidad de Montana, Missoula, United States
hcfmusp.author.externalLANA, F.:Instituto de Neuropsiquiatría y Adicciones (INAD), Parc de Salut Mar, Barcelona, Spain, Departamento de Psiquiatría, Universidad Autónoma de Barcelona, Barcelona, Spain
hcfmusp.author.externalEAP, C. B.:Unidad Farmacogenética y Psicofarmacología Clínica, Centro de Neurociencias Psiquiátricas, Hospital Universitario y Universidad de Lausanne, Switzerland, Centro de Investigación e Innovación en Ciencias Farmacéuticas Clínicas, Hospital Universitario y Universidad de Lausanne, Switzerland, Facultad de Ciencias Farmacéuticas, Universidad de Geneva, Switzerland, Instituto Farmacéutico de Ciencias del Oeste de Suiza, Universidad de Geneva, Universidad de Lausanne, Switzerland
hcfmusp.author.externalARROJO-ROMERO, M.:Departamento de Psiquiatría, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
hcfmusp.author.externalRăDULESCU, F.Ş.:Centro de Ciencias del Medicamento, Facultad de Farmacia, Universidad de Medicina y Farmacia Carol Davila, Bucharest, Romania
hcfmusp.author.externalSEIFRITZ, E.:Departamento de Psiquiatría, Psicoterapia y Psicosomáticos, Hospital Psiquiátrico, Universidad de Zürich, Zürich, Switzerland
hcfmusp.author.externalEVERY-PALMER, S.:Servicio Forense Regional Central Te Korowai Whāriki, Junta de Salud del Distrito Capital y Litoral, Wellington, New Zealand, Departamento de Medicina Psicológica, Universidad de Otago, Wellington, New Zealand
hcfmusp.author.externalBOUSMAN, C. A.:Departamentos de Medicina Genética, Psiquiatría, Fisiología y Farmacología, y Ciencias de la Salud Comunitaria, Universidad de Calgary, AB, Canada
hcfmusp.author.externalBEBAWI, E.:Facultad de Medicina, Universidad de Montreal, Montreal, Canada, Departamento de Farmacia, Hospital de Sacré-Cœur de Montréal, Montreal, Canada
hcfmusp.author.externalBHATTACHARYA, R.:Fundación NHS del Este del Londres, Londres, United Kingdom, Escuela de Medicina Barts, Universidad Queen Mary, Londres, United Kingdom
hcfmusp.author.externalKELLY, D. L.:Departamento de Psiquiatría, Facultad de Medicina, Centro de Investigación Psiquiátrica Maryland, Univversidad de Maryland, Baltimore, MD, United States
hcfmusp.author.externalOTSUKA, Y.:Departamento de Psiquiatría, Hospital General Asahi, Chiba, Japan
hcfmusp.author.externalLAZARY, J.:Departamento de Neurología y Neurocirugía, Instituto Nacional de Salud Mental, Budapest, Hungary
hcfmusp.author.externalTORRES, R.:Departamento de Psiquiatría, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile
hcfmusp.author.externalYECORA, A.:Secretaría de Salud Mental y Adicciones, Ministerio de Salud de la Provincia de Jujuy, San Salvador de Jujuy, Argentina
hcfmusp.author.externalMOTUCA, M.:Instituto Vilapriño, Centro de Estudios, Asistencia e Investigación en Neurociencias, Mendoza, Argentina
hcfmusp.author.externalCHAN, S. K. W.:Departamento de Psiquiatría, LSK Facultad de Medicina, Universidad de Hong Kong, Hong Kong, Laboratorio Estatal Clave de Ciencias Cerebrales y Cognitivas, Universidad de Hong Kong, Hong Kong
hcfmusp.author.externalZOLEZZI, M.:Facultad de Farmacia, Ciencias de la Salud, Universidad de Qatar, Doha, Qatar
hcfmusp.author.externalOUANES, S.:Departamento de Psiquiatría, Corporación Médica Hamad, Doha, Qatar
hcfmusp.author.externalBERARDIS, D. De:NHS, Departamento de Salud Mental, Hospital “G. Mazzini”, Teramo, Italy
hcfmusp.author.externalGROVER, S.:Departamento de Psiquiatría, Instituto de Postgrado en Educación e Investigación Médica, Chandigarh, India
hcfmusp.author.externalPROCYSHYN, R. M.:Instituto de Investigación sobre Salud Mental y Adicciones de la Columbia Británica, Departamento de Psiquiatría, Universidad de la Columbia Británica, Vancouver, BC, Canada
hcfmusp.author.externalADEBAYO, R. A.:Hospital Neuropsiquiátrico Federal de Yaba, Lagos, Nigeria
hcfmusp.author.externalKIRILOCHEV, O. O.:Departamento de Farmacología Clínica, Universidad Médica Estatal de Astrakhan, Astrakhan, Russian Federation
hcfmusp.author.externalSOLOVIEV, A.:Departamento de Psiquiatría y Psicología Clínica, Universidad Médica Estatal del Norte, Arkhangelsk, Russian Federation
hcfmusp.author.externalFOUNTOULAKIS, K. N.:3er Departamento de Psiquiatría, División de Neurociencias, Escuela de Medicina, Facultad de Ciencias de la Salud, Universidad Aristotle de Thessaloniki, Greece
hcfmusp.author.externalWILKOWSKA, A.:Departamento de Psiquiatría, Universidad Médica de Gdańsk, Gdańsk, Poland
hcfmusp.author.externalCUBAłA, W. J.:Departamento de Psiquiatría, Universidad Médica de Gdańsk, Gdańsk, Poland
hcfmusp.author.externalAYUB, M.:Departamento de Psiquiatría, Universidad de Queens, Kingston, Canada
hcfmusp.author.externalSILVA, A.:Departamento de Psiquiatría, Centro Hospitalario Universitario de, S. João, Porto, Portugal, Facultad de Medicina, Universidad de Porto, Porto, Portugal
hcfmusp.author.externalBONELLI, R. M.:Universidad Sigmund Freud, Vienna, Austria
hcfmusp.author.externalVILLAGRáN-MORENO, J. M.:Departamento de Neurociencias, Hospital Universitario Jerez, Servicio Andaluz de Salud, Universidad de Cadiz, Jerez, Spain
hcfmusp.author.externalCRESPO-FACORRO, B.:Departamento de Psiquiatría, Escuela de Medicina, Hospital Universitario Virgen del Rocio-IBIS, Sevilla, Spain, Red Española de Investigación en Salud Mental (CIBERSAM), Sevilla, Spain
hcfmusp.author.externalTEMMINGH, H.:Departamento de Psiquiatría y Salud Mental, Universidad de Cape Town, Hospital Valkenberg, Western Cape, Cape Town, South Africa
hcfmusp.author.externalDECLOEDT, E.:División de Farmacología Clínica, Departamento de Medicina, Facultad de Medicina y Ciencias de la Salud, Universidad de Stellenbosch, Cape Town, South Africa
hcfmusp.author.externalPEDRO, M. R.:Hospital Central de Maputo, Maputo, Mozambique
hcfmusp.author.externalTAKEUCHI, H.:Departamento de Neuropsiquiatría, Hospital Universitario de Keio, Tokyo, Japan
hcfmusp.author.externalTSUKAHARA, M.:Departamento de Psiquiatría, Centro Médico Psiquiátrico de Okayama, Okayama, Japan
hcfmusp.author.externalGRüNDER, G.:Instituto Central de Salud Mental, Departamento de Neuroimagen Molecular, Facultad de Medicina de Mannheim, Universidad de Heidelberg, Mannheim, Germany
hcfmusp.author.externalSAGUD, M.:Departamento de Psiquiatría, Facultad de Medicina, Universidad de Zagreb, Zagreb, Croatia, Departamento de Psiquiatría y Medicina Psicológica, Centro Hospitalario Universitario de Zagreb, Croatia
hcfmusp.author.externalCELOFIGA, A.:Departamento de Psiquiatría, Centro Médico Universitario Maribor, Maribor, Slovenia
hcfmusp.author.externalRISTIC, D. Ignjatovic:Facultad de Ciencias Médicas, Departamento de Psiquiatría, Universidad de Kragujevac, Kragujevac, Serbia
hcfmusp.author.externalORTIZ, B. B.:Grupo de Esquizofrenia Resistente (GER), Programa de Esquizofrenia (Proesq), Universidad Federal de Sao Paulo, SP, Brazil
hcfmusp.author.externalPALHA, A. J. Pacheco:Departamento e Instituto de Psiquiatría y Salud Mental, Facultad de Medicina de Oporto, Oporto, Portugal, Casa Salidedo Som Jesus (Hospital Psiquiátrico), Oporto, Portugal
hcfmusp.author.externalLLERENA, A.:INUBE Instituto de Investigación Biosanitaria de Extremadura, Escuela de Medicina, Hospital Universitario de Extremadura, Badajoz, Spain, Red Española de Investigación en Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcHELIO ELKIS
hcfmusp.description.articlenumber100415
hcfmusp.description.issue3
hcfmusp.description.volume30
hcfmusp.origemSCOPUS
hcfmusp.origem.dimensionspub.1163979994
hcfmusp.origem.scopus2-s2.0-85173287641
hcfmusp.relation.referencede Leon J., Schoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppala N., Et al., An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels, Pharmacopsychiatry., 55, 2, pp. 73-86, (2022)eng
hcfmusp.relation.referencede Leon J., Ruan C.J., Schoretsanitis G., De Las C.C., A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology, Psychother Psychosom, 89, 4, pp. 200-204, (2020)eng
hcfmusp.relation.referenceKane J., Honigfeld G., Singer J., Meltzer H., Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine, Arch Gen Psychiatry, 45, 9, pp. 789-796, (1988)eng
hcfmusp.relation.referencede Leon J., Ruan C.J., Schoretsanitis G., Kane J.M., Dose and safety concerns of clozapine: worldwide package inserts need revisions, Schizophr Res, 216, pp. 2-4, (2020)eng
hcfmusp.relation.referenceNielsen J., Young C., Ifteni P., Kishimoto T., Xiang Y.T., Schulte P.F., Et al., Worldwide differences in regulations of clozapine use, CNS Drugs, 30, 2, pp. 149-161, (2016)eng
hcfmusp.relation.referenceHowes O.D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N.J., Birnbaum M.L., Et al., Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on diagnosis and terminology, Am J Psychiatry, 174, 3, pp. 216-229, (2017)eng
hcfmusp.relation.referenceSiskind D., McCartney L., Goldschlager R., Kisely S., Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis, Br J Psychiatry, 209, 5, pp. 385-392, (2016)eng
hcfmusp.relation.referenceSamara M.T., Dold M., Gianatsi M., Nikolakopoulou A., Helfer B., Salanti G., Et al., Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis, JAMA Psychiatry, 73, 3, pp. 199-210, (2016)eng
hcfmusp.relation.referenceHuhn M., Nikolakopoulou A., Schneider-Thoma J., Krause M., Samara M., Peter N., Et al., Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis, Lancet., 394, 10202, pp. 939-951, (2019)eng
hcfmusp.relation.referenceLand R., Siskind D., McArdle P., Kisely S., Winckel K., Hollingworth S.A., The impact of clozapine on hospital use: a systematic review and meta-analysis, Acta Psychiatr Scand, 135, 4, pp. 296-309, (2017)eng
hcfmusp.relation.referenceMasuda T., Misawa F., Takase M., Kane J.M., Correll C.U., Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies, JAMA Psychiatry, 76, 10, pp. 1052-1062, (2019)eng
hcfmusp.relation.referenceRohde C., Polcwiartek C., Kragholm K., Ebdrup B.H., Siskind D., Nielsen J., Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study, Acta Psychiatr Scand, 137, 1, pp. 47-53, (2018)eng
hcfmusp.relation.referenceChopra N., Ruan C.J., McCollum B., Et al., High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers, Rev Colomb Psiquiatr, 49, pp. 84-95, (2020)eng
hcfmusp.relation.referenceSubramanian S., Vollm B.A., Huband N., Clozapine dose for schizophrenia, Cochrane Database Syst Rev, 6, 6, (2017)eng
hcfmusp.relation.referenceZhou Y., Ingelman-Sundberg M., Lauschke V.M., Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects, Clin Pharmacol Ther, 102, 4, pp. 688-700, (2017)eng
hcfmusp.relation.referenceAllorge D., Chevalier D., Lo-Guidice J.M., Cauffiez C., Suard F., Baumann P., Et al., Identification of a novel splice-site mutation in the CYP1A2 gene, Br J Clin Pharmacol, 56, 3, pp. 341-344, (2003)eng
hcfmusp.relation.referenceIto M., Katono Y., Oda A., Hirasawa N., Hiratsuka M., Functional characterization of 20 allelic variants of CYP1A2, Drug Metab Pharmacokinet, 30, 3, pp. 247-252, (2015)eng
hcfmusp.relation.referenceSoyama A., Saito Y., Hanioka N., Maekawa K., Komamura K., Kamakura S., Et al., Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population, Drug Metab Pharmacokinet, 20, 2, pp. 24-33, (2005)eng
hcfmusp.relation.referenceBender S., Eap C.B., Very high cytochrome P4501A2 activity and nonresponse to clozapine, Arch Gen Psychiatry, 55, 1, pp. 1048-1050, (1998)eng
hcfmusp.relation.referenceVanderZwaag C., McGee M., McEvoy J.P., Freudenreich O., Wilson W.H., Cooper T.B., Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges, Am J Psychiatry, 153, 12, pp. 1579-1584, (1996)eng
hcfmusp.relation.referenceCho J., Hayes R.D., Jewell A., Kadra G., Shetty H., MacCabe J.H., Et al., Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study, Acta Psychiatr Scand, 139, 3, pp. 237-247, (2019)eng
hcfmusp.relation.referenceWinckel K., Siskind D., Hollingworth S., Wheeler A., Clozapine-induced myocarditis: separating the wheat from the chaff, Aust N Z J Psychiatry, 49, 2, (2015)eng
hcfmusp.relation.referenceSchulte P., What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia, Clin Pharmacokinet, 42, 7, pp. 607-618, (2003)eng
hcfmusp.relation.referencede Leon J., Ruan C.J., Schoretsanitis G., Rohde C., Yagcioglu E.A., Baptista T., Et al., An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine, Gen Psychiatr, 35, 3, (2022)eng
hcfmusp.relation.referenceSchoretsanitis G., de Leon J., Best practices for starting clozapine in patients with schizophrenia: how to switch from the prior antipsychotic(s), J Clin Psychiatry, 834, (2022)eng
hcfmusp.relation.referencevan der Zalm Y., Foldager L., Termorshuizen F., Sommer I.E., Nielsen J., Selten J.P., Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study, Acta Psychiatr Scand, 143, 3, pp. 216-226, (2021)eng
hcfmusp.relation.referenceTaipale H., Tanskanen A., Mehtala J., Vattulainen P., Correll C.U., Tiihonen J., 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20), World Psychiatry, 19, 1, pp. 61-68, (2020)eng
hcfmusp.relation.referenceTiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Et al., 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), Lancet., 374, 9690, pp. 620-627, (2009)eng
hcfmusp.relation.referenceBachmann C.J., Aagaard L., Bernardo M., Brandt L., Cartabia M., Clavenna A., Et al., International trends in clozapine use: a study in 17 countries, Acta Psychiatr Scand, 136, 1, pp. 37-51, (2017)eng
hcfmusp.relation.referenceMeltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Et al., Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT), Arch Gen Psychiatry, 60, 1, pp. 82-91, (2003)eng
hcfmusp.relation.referenceCitrome L., Volavka J., Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine, Harv Rev Psychiatry, 29, pp. 20-34, (2021)eng
hcfmusp.relation.referenceHiemke C., Bergemann N., Clement H.W., Conca A., Deckert J., Domschke K., Et al., Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017, Pharmacopsychiatry., 51, 1-2, pp. 9-62, (2018)eng
hcfmusp.relation.referenceRonaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., McNeil J.J., A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls, Aust NZ J Psychiatry, 45, 6, pp. 458-465, (2011)eng
hcfmusp.relation.referenceSchoretsanitis G., Kane J.M., Correll C.U., Marder S.R., Citrome L., Newcomer J.W., Et al., Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie, J Clin Psychiatry, 81, 3, (2020)eng
hcfmusp.relation.referenceWilliams R.L., FDA position on product selection for “narrow therapeutic index” drugs, Am J Health-Syst Pharm, 54, 14, pp. 1630-1632, (1997)eng
hcfmusp.relation.referenceSpina E., Hiemke C., de Leon J., Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics, Expert Opin Drug Metab Toxicol, 12, 4, pp. 407-422, (2016)eng
hcfmusp.relation.referenceMoore T.J., Cohen M.R., Furberg C.D., Serious adverse drug events reported to the Food and Drug Administration, 1998-2005, Arch Intern Med, 167, 16, pp. 1752-1759, (2007)eng
hcfmusp.relation.referencede Leon J., Sanz E.J., De Las C.C., Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions, Schizophr Bull, 46, 1, pp. 1-3, (2020)eng
hcfmusp.relation.referencede Leon J., Sanz E.J., Noren G.N., De Las C.C., Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics, World Psychiatry, 19, 1, pp. 120-121, (2020)eng
hcfmusp.relation.referenceRohde C., Siskind D., de Leon J., Nielsen J., Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study, Acta Psychiatr Scand, 142, 2, pp. 78-86, (2020)eng
hcfmusp.relation.referenceVillasante-Tezanos A.G., Rohde C., Nielsen J., de Leon J., Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia, Acta Psychiatr Scand, 142, 1, pp. 66-67, (2020)eng
hcfmusp.relation.referenceSchoretsanitis G., Ruan C.J., Rohde C., Verdoux H., De Las C.C., Spina E., Et al., An update on the complex relationship between clozapine and pneumonia, Expert Rev Clin Pharmacol, 14, 2, pp. 145-149, (2021)eng
hcfmusp.relation.referenceVohra J., Sudden cardiac death in schizophrenia: a review, Heart Lung Circ, 29, 10, pp. 1427-1432, (2020)eng
hcfmusp.relation.referenceRonaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., Wolfe R., McNeil J.J., Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study, Schizophr Res, 141, 2-3, pp. 173-178, (2012)eng
hcfmusp.relation.referencePapola D., Ostuzzi G., Gastaldon C., Morgano G.P., Dragioti E., Carvalho A.F., Et al., Antipsychotic use and risk of life- threatening medical events: umbrella review of observational studies, Acta Psychiatr Scand, 140, 3, pp. 227-243, (2019)eng
hcfmusp.relation.referenceMyles N., Myles H., Xia S., Large M., Bird R., Galletly C., Et al., A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia, Aust N Z J Psychiatry, 53, 5, pp. 403-412, (2019)eng
hcfmusp.relation.referenceWicinski M., Weclewicz M.M., Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring, Curr Opin Hematol, 25, 1, pp. 22-28, (2018)eng
hcfmusp.relation.referenceShirazi A., Stubbs B., Gomez L., Moore S., Gaughran F., Flanagan R.J., Et al., Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis, Int J Mol Sci, 17, 6, (2016)eng
hcfmusp.relation.referenceWest S., Rowbotham D., Xiong G., Kenedi C., Clozapine induced gastrointestinal hypomotility: a potentially life threatening adverse event. A review of the literature, Gen Hosp Psychiaty, 46, pp. 32-37, (2017)eng
hcfmusp.relation.referenceCohen D., Clozapine and gastrointestinal hypomotility, CNS Drugs, 31, 12, pp. 1083-1091, (2017)eng
hcfmusp.relation.referencede Leon J., Schoretsanitis G., Kane J.M., Ruan C.J., Using therapeutic drug monitoring to personalize clozapine dosing in Asians, Asia Pac Psychiatry, 12, 2, (2020)eng
hcfmusp.relation.referenceSpina E., de Leon J., Clinically relevant interactions between newer antidepressants and second-generation antipsychotics, Expert Opin Drug Metab Toxicol, 10, 5, pp. 721-746, (2014)eng
hcfmusp.relation.referencePacia S.V., Devinsky O., Clozapine-related seizures: experience with 5,629 patients, Neurology., 44, 12, pp. 2247-2249, (1994)eng
hcfmusp.relation.referenceClancy M.J., Clarke M.C., Connor D.J., Cannon M., Cotter D.R., The prevalence of psychosis in epilepsyeng
hcfmusp.relation.referenceFaber M.S., Fuhr U., Time response of cytochrome P450 1A2 activity on cessation of heavy smoking, Clin Pharmacol Ther, 76, 2, pp. 178-184, (2004)eng
hcfmusp.relation.referencea systematic review and meta-analysis, BMC Psychiatry, 14, (2014)eng
hcfmusp.relation.referenceAsenjo Lobos C., Komossa K., Rummel-Kluge C., Hunger H., Schmid F., Schwarz S., Et al., Clozapine versus other atypical antipsychotics for schizophrenia, Cochrane Database Syst Rev, 11, (2010)eng
hcfmusp.relation.referenceTrifiro G., Spina E., Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems, Curr Drug Metab, 12, 7, pp. 611-620, (2011)eng
hcfmusp.relation.referenceNielsen J., Correll C.U., Manu P., Kane J.M., Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?, J Clin Psychiatry, 74, 6, pp. 603-613, (2013)eng
hcfmusp.relation.referenceSabaawi M., Singh N.N., de Leon J., Guidelines for the use of clozapine in individuals with developmental disabilities, Res Dev Disabil, 27, 3, pp. 309-336, (2006)eng
hcfmusp.relation.referenceBertilsson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., Et al., Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test, Br J Clin Pharmacol, 38, 5, pp. 471-473, (1994)eng
hcfmusp.relation.referenceGhotbi R., Christensen M., Roh H.K., Ingelman-Sundberg M., Aklillu E., Bertilsson L., Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans, Eur J Clin Pharmacol, 63, 6, pp. 537-546, (2007)eng
hcfmusp.relation.referencePerry P.J., Bever K.A., Arndt S., Combs M.D., Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram, Biol Psychiatry, 44, 8, pp. 733-738, (1998)eng
hcfmusp.relation.referenceHaslemo T., Eikeseth P.H., Tanum L., Molden E., Refsum H., The effect of variable cigarette consumption on the interaction with clozapine and olanzapine, Eur J Clin Pharmacol, 62, 12, pp. 1049-1053, (2006)eng
hcfmusp.relation.referenceDobrinas M., Cornuz J., Oneda B., Kohler Serra M., Puhl M., Eap C.B., Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility, Clin Pharmacol Ther, 90, 1, pp. 117-125, (2011)eng
hcfmusp.relation.referenceRuan C.J., Wang C.Y., Tang Y.L., Lin S.K., Lee S.T., Hong K.S., Et al., Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13, J Clin Psychopharmacol, 39, 6, pp. 644-648, (2019)eng
hcfmusp.relation.referenceWagner E., McMahon L., Falkai P., Hasan A., Siskind D., Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis, Acta Psychiatr Scand, 142, 6, pp. 456-466, (2020)eng
hcfmusp.relation.referenceOlesen O.V., Linnet K., Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations, J Clin Pharmacol, 41, 8, pp. 823-832, (2001)eng
hcfmusp.relation.referenceSchoretsanitis G., Kane J.M., Ruan C.J., Spina E., Hiemke C., de Leon J., Comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients, Expert Rev Clin Pharmacol, 12, 7, pp. 603-621, (2019)eng
hcfmusp.relation.referenceChang W.H., Lin S.K., Lane H.Y., Wei F.C., Hu W.H., Lam Y.W., Et al., Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients, Prog Neuro-Psychopharmacol Biol Psychiatry, 22, 5, pp. 723-739, (1998)eng
hcfmusp.relation.referencede Leon J., Glucuronidation enzymes, genes and psychiatry, Int J Neuropsychopharmacol, 6, 1, pp. 57-72, (2003)eng
hcfmusp.relation.referenceLoi C.M., Smith D.A., Dalvie D., Which metabolites circulate?, Drug Metab Dispos, 41, 5, pp. 933-951, (2013)eng
hcfmusp.relation.referenceSchaber G., Stevens I., Gaertner H.J., Dietz K., Breyer-Pfaff U., Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance, Br J Clin Pharmacol, 46, 5, pp. 453-459, (1998)eng
hcfmusp.relation.referenceKuoppamaki M., Syvalahti E., Hietala J., Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists, Eur J Pharmacol, 245, 2, pp. 179-182, (1993)eng
hcfmusp.relation.referenceRuan C.J., Zang Y.N., Wang C.Y., Cheng Y.H., Sun C., Spina E., Et al., Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review, J Clin Psychopharmacol, 39, 2, pp. 135-144, (2019)eng
hcfmusp.relation.referenceJerling M., Lindstrom L., Bondesson U., Bertilsson L., Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from therapeutic drug monitoring service, Ther Drug Monit, 169, 4, pp. 368-374, (1994)eng
hcfmusp.relation.referencede Leon J., Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid, Ther Drug Monit, 42, 1, pp. 159-161, (2020)eng
hcfmusp.relation.referenceSpina E., Barbieri M.A., Cicala G., de Leon., Clinically relevant interactions between atypical antipsychotics and anti-infective agents, Pharmaceuticals (Basel), 13, 12, (2020)eng
hcfmusp.relation.referenceRuan C.J., Zang Y.N., Cheng Y.H., de Leon J., Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment, Psychother Psychosom, 89, 4, pp. 255-257, (2020)eng
hcfmusp.relation.referencede Leon J., Atypical antipsychotic dosing: the effect of smoking and caffeine, Psychiatr Serv, 55, 5, pp. 491-493, (2004)eng
hcfmusp.relation.referenceFacciola G., Avenoso A., Scordo M.G., Madia A.G., Ventimiglia A., Perucca E., Et al., Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders, Ther Drug Monit, 21, 3, pp. 341-345, (1999)eng
hcfmusp.relation.referenceWong J.O., Leung S.P., Mak T., Ng R.M., Chan K.T., Hon-Kee Cheung H., Et al., Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients, Prog Neuro-Psychopharmacol Biol Psychiatry, 30, 2, pp. 251-264, (2006)eng
hcfmusp.relation.referenceDiaz F.J., Santoro V., Spina E., Cogollo M., Rivera T.E., Botts S., Et al., Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables, Pharmacopsychiatry., 41, 3, pp. 81-91, (2008)eng
hcfmusp.relation.referenceRajkumar A.P., Poonkuzhali B., Kuruvilla A., Jacob M., Jacob K.S., Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia, Int Clin Psychopharmacol, 28, 1, pp. 50-56, (2013)eng
hcfmusp.relation.referenceSpina E., D'Arrigo C., Santoro V., Muscatello M.R., Pandolfo G., Zoccali R., Et al., Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder, Ther Drug Monit, 31, 6, pp. 758-763, (2009)eng
hcfmusp.relation.referenceDiaz F.J., Josiassen R.C., de Leon J., The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial, J Clin Psychopharmacol, 38, 5, pp. 442-446, (2018)eng
hcfmusp.relation.referenceKuzin M., Haen E., Hiemke C., Bochon B., Bochon K., Grunder G., Paulzen M., Et al., Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis, J Psychopharmacol, 35, 3, pp. 273-278, (2021)eng
hcfmusp.relation.referenceMeltzer H.Y., Clozapine: balancing safety with superior antipsychotic efficacy, Clin Schizophr Relat Psychoses, 6, 3, pp. 134-144, (2012)eng
hcfmusp.relation.referenceZarezadeh M., Saedisomeolia A., Shekarabi M., Et al., The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies, Eur J Nutr, 60, 6, pp. 2905-2921, (2021)eng
hcfmusp.relation.referenceMoschny N., Hefner G., Grohmann R., Eckermann G., Maier H.B., Seifert J., Et al., Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics, Pharmaceuticals (Basel), 14, 6, (2021)eng
hcfmusp.relation.referenceClark S.R., Warren N.S., Kim G., Schubert K.O., Kisely S., Forrester T., Et al., Elevated clozapine levels associated with infection: a systematic review, Schizophr Res, 192, pp. 50-56, (2018)eng
hcfmusp.relation.referenceNielsen R., Akey J.M., Jakobsson M., Pritchard J.K., Tishkoff S., Willerslev E., Tracing the peopling of the world through genomics, Nature., 541, 7637, pp. 302-310, (2017)eng
hcfmusp.relation.referencede Leon J., Rajkumar A.P., Kaithi A.R., Schoretsanitis G., Kane J.M., Wang C.Y., Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview, Indian J Psychol Med, 42, 1, pp. 4-10, (2020)eng
hcfmusp.relation.referenceSuhas S., Kumar V., Damodharan D., Sharma P., Rao N.P., Varambally S., Et al., Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level?An exploratory study, Schizophr Res, 222, pp. 195-201, (2020)eng
hcfmusp.relation.referenceGonzalez-Esquivel D.F., Jung-Cook H., Baptista T., de Leon J., Amerindians may need clozapine dosing similar to that of Asians, Rev Psiquiatr Salud Ment, 14, 3, pp. 177-179, (2021)eng
hcfmusp.relation.referenceMenkes D.B., Glue P., Gale C., Lam F., Hung C.T., Hung N., Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients, EBioMedicine., 27, pp. 134-137, (2018)eng
hcfmusp.relation.referenceZang Y.N., Dong F., Li A.N., Wang C.Y., Guo G.X., Wang Q., Et al., The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients, Eur J Drug Metab Pharmacokinet, 46, 3, pp. 353-371, (2021)eng
hcfmusp.relation.referenceSathirakul K., Chan C., Teng L., Bergstrom R.F., Yeo K.P., Wise S.D., Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects, Br J Clin Pharmacol, 56, 2, pp. 184-187, (2003)eng
hcfmusp.relation.referenceMarder S.R., Yang Y.S., Chapter 25. Clozapine, The American Psychiatric Association Publishing textbook of psychopharmacology, pp. 623-648, (2017)eng
hcfmusp.relation.referenceBigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Et al., Sex, race, and smoking impact olanzapine exposure, J Clin Pharmacol, 48, 2, pp. 157-165, (2008)eng
hcfmusp.relation.referenceRuan C.J., de Leon J., Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?, Pharmacogenomics., 21, 6, pp. 369-373, (2020)eng
hcfmusp.relation.referenceThe Dutch Pharmacogenomic Working Group, Phamacogenomic recommendations, farmacogenetica-update, (2020)eng
hcfmusp.relation.referenceDobrinas M., Cornuz J., Eap C.B., Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers, Pharmacogenet Genomics, 23, 5, pp. 286-292, (2013)eng
hcfmusp.relation.referenceJakobsen M.I., Larsen J.R., Svensson C.K., Johansen S.S., Linnet K., Nielsen J., Et al., The significance of sampling time in therapeutic drug monitoring of clozapine, Acta Psychiatr Scand, 135, 2, pp. 159-169, (2017)eng
hcfmusp.relation.referenceSchoretsanitis G., Smith R.L., Molden E., Solismaa A., Seppala N., Kopecek M., Et al., European Caucasians may need lower minimum therapeutic clozapine doses than those customarily proposed, J Clin Psychopharmacol, 41, 2, pp. 140-147, (2021)eng
hcfmusp.relation.referenceRostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., Flanagan R.J., Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients, J Clin Psychopharmacol, 24, 1, pp. 70-78, (2004)eng
hcfmusp.relation.referenceQuiles C., Verdoux H., La clozapine, (2020)eng
hcfmusp.relation.referenceGuideline for the use of clozapine [Internet]eng
hcfmusp.relation.referenceTaylor D.M., Barnes T.R.E., Young A.H., Maudsley prescribing guidelines in psychiatry, (2018)eng
hcfmusp.relation.referenceMeyer J.M., Stahl S.M., The clozapine handbook: Stahl's handbooks (Stahl's essential psychopharmacology handbooks), (2020)eng
hcfmusp.relation.referenceLieberman J.A., Kane J.M., Johns C.A., Clozapine: guidelines for clinical management, J Clin Psychiatry, 50, 9, pp. 329-338, (1989)eng
hcfmusp.relation.referenceBaldessarini R.J., Frankenburg F.R., Clozapine. A novel antipsychotic agent, N Engl J Med, 324, 11, pp. 746-754, (1991)eng
hcfmusp.relation.referenceCitrome L., Schizophrenia life-threatening and life-saving treatment?, Curr Psychiatr Ther, 8, 12, pp. 57-63, (2009)eng
hcfmusp.relation.referencede Leon J., Armstrong S.C., Cozza K.L., The dosing of atypical antipsychotics, Psychosomatics., 46, 3, pp. 262-273, (2005)eng
hcfmusp.relation.referenceSimpson G.M., Josiassen R.C., Stanilla J.K., de Leon J., Nair C., Abraham G., Et al., Double-blind study of clozapine dose response in chronic schizophrenia, Am J Psychiatry, 156, 11, pp. 1744-1750, (1999)eng
hcfmusp.relation.referenceCohen D., Bogers J.P., van Dijk D., Bakker B., Schulte P.F., Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy, J Clin Psychiatry, 73, 10, pp. 1307-1312, (2012)eng
hcfmusp.relation.referenceSiskind D., Sidhu A., Cross J., Chua Y.T., Myles N., Cohen D., Et al., Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy, Aust N Z J Psychiatry, 54, 5, pp. 467-481, (2020)eng
hcfmusp.relation.referenceWang X.Q., Lv B., Wang H.F., Zhang X., Yu S.Y., Huang X.S., Et al., Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014, J Clin Neurosci, 22, 6, pp. 1005-1011, (2015)eng
hcfmusp.relation.referenceFreudenreich O., Clozapine-induced myocarditis: prescribe safely but do prescribe, Acta Psychiatr Scand, 132, 4, pp. 240-241, (2015)eng
hcfmusp.relation.referencede Leon J., Tang Y.L., Baptista T., Cohen D., Schulte P.F., Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations, Acta Psychiatr Scand, 132, 4, pp. 242-243, (2015)eng
hcfmusp.relation.referenceHjorthoj C., Sturup A.E., McGrath J.J., Nordentoft M., Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry, 4, 4, pp. 295-301, (2017)eng
hcfmusp.relation.referenceBandelow B., Degner D., Kreusch U., Ruther E., Myocarditis under therapy with clozapine, Schizophr Res, 17, 3, pp. 293-294, (1995)eng
hcfmusp.relation.referencePui-yin Chung J., Shiu-yin Chong C., Chung K.F., Lai-wah Dunn E., Wai-nang Tang O., Chan W.F., The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong, Can J Psychiatr, 53, 12, pp. 857-862, (2008)eng
hcfmusp.relation.referenceIfteni P., Nielsen J., Burtea V., Correll C.U., Kane J.M., Manu P., Effectiveness and safety of rapid clozapine titration in schizophrenia, Acta Psychiatr Scand, 130, 1, pp. 25-29, (2014)eng
hcfmusp.relation.referenceIfteni P., Correll C.U., Nielsen J., Burtea V., Kane J.M., Manu P., Rapid clozapine titration in treatment-refractory bipolar disorder, J Affect Disord, 166, pp. 168-172, (2014)eng
hcfmusp.relation.referenceAksoy Poyraz C., Turan S., Demirel O.F., Usta Saglam N.G., Yildiz N., Duran A., Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series, Ther Adv Psychopharmacol, 5, 4, pp. 237-242, (2015)eng
hcfmusp.relation.referenceLochhead J.D., Nelson M.A., Schneider A.L., Risks and benefits of rapid clozapine titration, Ment Illn, 8, 1, (2016)eng
hcfmusp.relation.referenceChopra N., de Leon J., Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy, Int J Psychiatry Med, 51, 1, pp. 104-115, (2016)eng
hcfmusp.relation.referencePoyraz C.A., Ozdemir A., Saglam N.G., Turan S., Poyraz B.C., Tomruk N., Et al., Rapid clozapine titration in patients with treatment refractory schizophrenia, Psychiatr Q, 87, 2, pp. 315-322, (2016)eng
hcfmusp.relation.referencede Leon J., Rhee D.W., Kondracke A., Diuguid-Gerber J., Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York Hospital, Psychosomatics., 61, 1, pp. 102-103, (2020)eng
hcfmusp.relation.referenceDanilewitz M., Rafizadeh R., Bousman C.A., Successful clozapine rechallenge after suspected clozapine-associated myocarditis: a case report, J Clin Psychopharmacol, 41, 2, pp. 218-220, (2021)eng
hcfmusp.relation.referenceVermeulen J.M., van Rooijen G., van de Kerkhof M.P.J., Sutterland A.L., Correll C.U., de Haan L., Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years, Schizophr Bull, 45, 2, pp. 315-329, (2019)eng
hcfmusp.relation.referenceVerdoux H., Quiles C., de Leon J., Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review, Schizophr Res, 211, pp. 1-9, (2019)eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationbc3f7160-1748-4808-b40a-69194f13212b
relation.isAuthorOfPublication.latestForDiscoverybc3f7160-1748-4808-b40a-69194f13212b
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - ODS/03